RELIEF THERAPEUTICS Holding SA represents values and a corporate philosophy rooted in the commitment to provide innovative therapeutic solutions for unmet medical needs. As a reputable pharmaceutical company, RELIEF THERAPEUTICS focuses on developing and commercializing novel drugs to alleviate patient suffering and improve quality of life. With a strong emphasis on research and development, their pipeline of potential therapies demonstrates a dedication to scientific excellence and improving patient outcomes. Furthermore, RELIEF THERAPEUTICS prioritizes collaboration with key stakeholders, including healthcare professionals, regulatory authorities, and patients, to ensure the highest standards of ethical conduct and patient-centered care.

RELIEF THERAPEUTICS Holding SA primarily operates in Switzerland.

RELIEF THERAPEUTICS Holding SA has achieved several significant milestones. Firstly, the company successfully developed and obtained FDA approval for their lead drug candidate, RLF-100, also known as Aviptadil, for the treatment of respiratory distress in COVID-19 patients. Additionally, RELIEF THERAPEUTICS entered into a partnership with NeuroRx, Inc. to advance RLF-100's development and commercialization in the United States. The company also received orphan drug designation from the FDA for RLF-100 to treat Acute Respiratory Distress Syndrome (ARDS). Furthermore, RELIEF THERAPEUTICS has collaborated with prominent medical institutions to conduct clinical trials and expand the application of RLF-100 beyond COVID-19. These achievements position RELIEF THERAPEUTICS as a promising player in the biopharmaceutical industry.

RELIEF THERAPEUTICS Holding SA is a pharmaceutical company with a rich history and background. Established in the year [insert year], RELIEF THERAPEUTICS has dedicated itself to the research and development of innovative therapies to address various medical conditions. The company has garnered extensive expertise in identifying and advancing novel drug candidates, focusing primarily on diseases with high unmet medical needs. RELIEF THERAPEUTICS has established strategic collaborations and partnerships to further expand its reach and accelerate the development of its pipeline products. With a dedicated team of scientists and professionals, the company strives to provide breakthrough solutions for patients worldwide, aligning with its mission to improve healthcare outcomes globally.

The main competitors of RELIEF THERAPEUTICS Holding SA in the market are other pharmaceutical companies operating in the same therapeutic areas. It is important to note that the competitive landscape may vary depending on the specific product or indication.

RELIEF THERAPEUTICS Holding SA is primarily active in the biotechnology and pharmaceutical industries.

The business model of RELIEF THERAPEUTICS Holding SA focuses on the development of innovative therapeutics for various medical conditions. The company primarily specializes in the field of neurology and aims to provide relief to patients suffering from debilitating diseases. RELIEF THERAPEUTICS Holding SA leverages its expertise in drug development and strategic partnerships to advance its pipeline of promising therapeutic candidates. By prioritizing research and innovation, the company aims to address unmet medical needs and improve the quality of life for patients. Through its dedication to discovering novel treatments, RELIEF THERAPEUTICS Holding SA aims to contribute significantly to the healthcare industry.

RELIEF THERAPEUTICS Holding KGV ir -1162,15.

RELIEF THERAPEUTICS Holding KUV ir 0,29.

AlleAktien kvalitātes vērtējums RELIEF THERAPEUTICS Holding ir 3/10.

gaidāmā RELIEF THERAPEUTICS Holding apgrozījums ir 44,15 milj. CHF.

gaidāmā RELIEF THERAPEUTICS Holding peļņa ir -11 123,97 CHF.

RELIEF THERAPEUTICS Holding SA is a Swiss biotech company specializing in the development of drugs for the treatment of neurological and inflammatory diseases. It was founded in 2016 and has been listed on the Swiss stock exchange SIX since 2019. The activities of RELIEF THERAPEUTICS include several areas, from research and development of new drugs to the marketing of already approved products. The company has an internationally experienced team of researchers, developers, and experts focusing on the identification and development of innovative substances. RELIEF THERAPEUTICS focuses on the development of therapies for the treatment of inflammatory and autoimmune diseases, particularly Crohn's disease, autism, multiple sclerosis, and respiratory diseases such as asthma and COPD. The company has several promising products in its pipeline, currently in various stages of clinical trials. One of the key products of RELIEF THERAPEUTICS is RLF-100 (Aviptadil), currently in clinical development for the treatment of COVID-19. RLF-100 is a synthetic peptide molecule capable of reducing the concentration of the pro-inflammatory molecule tumor necrosis factor-alpha, thereby improving lung function and oxygen uptake. Another important product of RELIEF THERAPEUTICS is Atexakin alfa (RLF-1002), a synthetic peptide molecule in development for the treatment of Crohn's disease and other inflammatory bowel diseases. Atexakin alfa targets the interleukin-6 signaling pathway, which plays a crucial role in the development of inflammation. Furthermore, RELIEF THERAPEUTICS is working on the development of a novel treatment for autism. The company has partnered with biotech company Neurimmune to develop antibodies against the protein C4A, believed to play a significant role in the development of autism. Another important business area for RELIEF THERAPEUTICS is the licensing of already approved products. The company has entered into an agreement with Swiss biotech company Altavant Sciences to license the drug Roxybond, used for pain treatment. Overall, RELIEF THERAPEUTICS has a promising portfolio of products and developments in various medical fields. Through consistent investment in research and development and collaboration with top-notch partners and experts, the company aims to further strengthen its position as a leading provider of innovative therapies.

RELIEF THERAPEUTICS Holding izmaksā dividendes 0 CHF, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt RELIEF THERAPEUTICS Holding vai uzņēmums nedod dividendes.

RELIEF THERAPEUTICS Holding ISIN ir CH0100191136.

RELIEF THERAPEUTICS Holding WKN ir A1H80W.

RELIEF THERAPEUTICS Holding simbols ir RLF.SW.

Pēdējo 12 mēnešu laikā RELIEF THERAPEUTICS Holding maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos RELIEF THERAPEUTICS Holding plāno maksāt dividendes 0 CHF apmērā.

RELIEF THERAPEUTICS Holding pašreizējā dividendu rentabilitāte ir .

RELIEF THERAPEUTICS Holding maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

RELIEF THERAPEUTICS Holding pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 CHF. Tas atbilst dividendes ražībai 0 %.

RELIEF THERAPEUTICS Holding tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu RELIEF THERAPEUTICS Holding apmērā 0 CHF, kas tika izmaksāta 6.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 6.08.2024..

Pēdējās dividendes izmaksa notika 6.08.2024..

Gadā 2023, RELIEF THERAPEUTICS Holding izmaksāja 0 CHF dividendes.

RELIEF THERAPEUTICS Holding dividendes tiek izmaksātas CHF.